

Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

SaOS-2

RRID:CVCL_0548

Type: Cell Line

Proper Citation

RRID:CVCL_0548

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0548

Proper Citation: RRID:CVCL_0548

Description: Cell line SaOS-2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Osteosarcoma

Defining Citation: [PMID:833871](#), [PMID:2233717](#), [PMID:2823272](#), [PMID:3040234](#), [PMID:3518877](#), [PMID:6935474](#), [PMID:7017212](#), [PMID:8617485](#), [PMID:10763916](#), [PMID:11416159](#), [PMID:12645653](#), [PMID:15150091](#), [PMID:15736406](#), [PMID:15939397](#), [PMID:16888811](#), [PMID:17354236](#), [PMID:17431109](#), [PMID:17981215](#), [PMID:19787792](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:21519327](#), [PMID:22075555](#), [PMID:23144859](#), [PMID:23671654](#), [PMID:24758355](#), [PMID:25031706](#), [PMID:26320182](#), [PMID:26351324](#), [PMID:27397505](#), [PMID:29334376](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SaOS-2

Synonyms: SAOS-2, Saos-2, SAOS 2, Saos 2, Saos2, SaOs2, SAOS2, Sarcoma Osteogenic-2, SaOS, SAOS

Cross References: BTO:BTO_0000971, CLO:CLO_0008947, CLO:CLO_0050140, EFO:EFO_0022402, MCCL:MCC:0000449, CLDB:cl4250, CLDB:cl4251, CLDB:cl4252, CLDB:cl5281, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-7939, ATCC:HTB-85, BCRJ:0217, BioSample:SAMN01821594, BioSample:SAMN01821661, BioSample:SAMN03471126, BioSample:SAMN10987923, cancercellines:CVCL_0548, CancerTools:161931, CCRID:1101HUM-PUMC000025, CCRID:3101HUMSCSP5057, CCRID:3101HUMTCHu114, CCRID:4201HUM-CCTCC00075, CCTCC:GDC0075, Cell_Model_Passport:SIDM01084, ChEMBL-Cells:ChEMBL3307737, ChEMBL-Targets:ChEMBL614894, CLS:300331, Cosmic:687930, Cosmic:755311, Cosmic:897500, Cosmic:909707, Cosmic:931039, Cosmic:931912, Cosmic:1044086, Cosmic:1044269, Cosmic:1070841, Cosmic:1074395, Cosmic:1082492, Cosmic:1529898, Cosmic:1733126, Cosmic:2301582, Cosmic:2816206, Cosmic-CLP:909707, DepMap:ACH-000410, DSMZ:ACC-243, DSMZCellDive:ACC-243, ECACC:89050205, EGA:EGAS00001000978, GDSC:909707, GEO:GSM170249, GEO:GSM185150, GEO:GSM185151, GEO:GSM320830, GEO:GSM827588, GEO:GSM879222, GEO:GSM1639703, GEO:GSM1639704, GEO:GSM1670401, GEO:GSM1676314, GEO:GSM1701648, GEO:GSM1915012, GEO:GSM1915013, IARC_TP53:21653, ICLC:HTL01001, IZSLER:BS TCL 90, KCB:KCB 200550YJ, KCLB:30085, KCLB:80023, LiGeA:CCLE_519, LINCS_LDP:LCL-1430, Lonza:747, NCBI_Iran:C453, PharmacDB:Saos2_1343_2019, PRIDE:PXD016398, PRIDE:PXD017130, PRIDE:PXD021564, PRIDE:PXD025970, PRIDE:PXD030304, Progenetix:CVCL_0548, PubChem_Cell_line:CVCL_0548, RCB:RCB0428, RCB:RCB3688, TKG:TKG 0469, TOKU-E:3085, Ubigene:YC-D017, Wikidata:Q7420876

ID: CVCL_0548

Record Creation Time: 20220427T221515+0000

Record Last Update: 20260829T235814+0000

Ratings and Alerts

No rating or validation information has been found for SaOS-2.

Warning: Discontinued: ATCC; CRL-7939

Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). **Warning:** Discontinued: KCLB; 80023
Population: Caucasian., From: Memorial Sloan Kettering Cancer Center; New York; USA., Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 1037 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Horak I, et al. (2026) Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2-COL3A1 axis. *Molecular oncology*.

Guo L, et al. (2026) The ITGB2-COPS3-SOX2 Axis and SOX2 Liquid-Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(29), e20913.

Pannese M, et al. (2026) Impaired collagen deposition in the absence of ERp44. *iScience*, 29(5), 115736.

Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. *Cancer research*, 86(9), 2161.

Ross AC, et al. (2026) Modulating Galectin-1 in human osteoblast-like cells alters mineralisation and influences the expression of genes associated with osteoblasts and osteocytes. *Bioscience reports*, 46(3).

Wang J, et al. (2026) Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. *Science progress*, 109(2), 368504261464856.

Ross AC, et al. (2026) Genes Associated With Fracture Risk in Thoroughbred Horses Have Novel Roles in Osteogenesis. *Animal genetics*, 57(4), e70166.

Nørregaard KS, et al. (2026) The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells. *Molecular cancer therapeutics*, 25(1), 140.

Dias FG, et al. (2026) In Vitro Biological Evaluation of Titanium Implants Anodized With Aqueous Extract of Psidium guajava and Conventional Electrolytes. *International journal of biomaterials*, 2026, 5522753.

Zhou Y, et al. (2026) Distinct Regulation of the ARF and TAp73 Tumor Suppressor Genes by the Transcription Factor E2F1 Enables Discrimination of Cancer Cells from Normal Growing Cells. *Cells*, 15(1).

Peng M, et al. (2026) In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma. *bioRxiv : the preprint server for biology*.

Dulta K, et al. (2026) To Dye or Not to Dye: Unraveling the Impact of Surface Chemistry on Cerium Oxide Nanoparticles-Cell Interactions. *Small science*, 6(2), e202500446.

Kostas M, et al. (2026) Unconventional activation of the proto-oncogene FGFR1 by extracellular phosphate via H2O2-mediated kinase oxidation. *Cell reports*, 45(6), 117504.

Aderhold N, et al. (2026) Combined Inhibition of ATR and Ribonucleotide Reductase Induces Synergistic Antineoplastic Activity in Osteosarcoma Cells. *Cancer reports* (Hoboken, N.J.), 9(5), e70568.

Güngör Ö, et al. (2026) Triphenylphosphonium-triazole hybrids as mitochondria-targeted anticancer agents: design, DNA binding, cytotoxicity study, fluorescent apoptosis imaging and molecular docking. RSC advances.

Azeroglu B, et al. (2025) Conserved and unique features of terminal telomeric sequences in ALT-positive cancer cells. eLife, 14.

Abuetabh Y, et al. (2025) Deciphering UBE4B phosphorylation dynamics: a key mechanism in p53 accumulation and cancer cell response to DNA damage. Cell death discovery, 11(1), 131.

Gospos J, et al. (2025) Dynamic assessment of a humanized bone tumour microenvironment reveals insights into osteosarcoma primary tumour remodelling and lung metastases. Scientific reports, 15(1), 45619.

Brdar A, et al. (2025) p53 isoforms have a high aggregation propensity, interact with chaperones and lack binding to p53 interaction partners. eLife, 13.

Noh M, et al. (2025) Dimeric R25CPTH(1-34) activates the parathyroid hormone-1 receptor in vitro and stimulates bone formation in osteoporotic female mice. eLife, 13.